1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Pfizer’s RSV Vaccine: Two Positive Votes Don’t Necessarily Add Up To AdComm Endorsement

 
• By Sarah Karlin-Smith

Pfizer got positive standalone votes on safety and efficacy for its RSV vaccine in older adults at a US FDA advisory committee, but only three advisors – a minority of the 12-member panel – endorsed both the safety and effectiveness of the firm’s candidate.

math equation without the answer
VRBPAC vote totals obscure panel’s conflicted stance on Pfizer’s RSV vaccine • Source: Shutterstock

Pfizer Inc.’s respiratory syncytial virus (RSV) vaccine for older adults got two positive votes at a 28 February US Food and Drug Administration advisory panel. The company spun that into the Vaccine and Related Biological Products Advisory Committee’s endorsement of approval for the vaccine, but a closer examination of the two votes paints a much more complicated picture.

The VRBPAC voted 7-4 with one abstention that the available data are adequate to support the safety of Pfizer’s Abrysvo (RSVPreF) when administered to individuals 60 years of age and older for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers